The short answer: repair tissue quality

Microfracture has been the standard first-line treatment for focal cartilage defects for decades, and for many patients it works well — at least initially. So why are specialists increasingly reaching for something different?

The answer comes down to the type of tissue each approach produces. Microfracture works by making small perforations in the bone beneath the defect, releasing marrow-derived stem cells that fill the gap. Those cells mature into fibrocartilage — a scar-like tissue dominated by Type I collagen and relatively low in the glycosaminoglycans that give healthy cartilage its load-bearing resilience. It fills the hole, but it is not the same material as what was lost.

A ChondroFiller injection takes a different route entirely. The acellular collagen scaffold is placed directly into the defect without disturbing the underlying bone. Over 6–12 months, the patient's own progenitor cells migrate into it and deposit a more hyaline-like matrix — closer in composition to original articular cartilage.

In the first 12–18 months, both approaches can produce comparable symptom relief. The gap tends to open between years two and five, as fibrocartilage progressively degrades under joint load. That is not a failure of microfracture technique — it is simply the natural history of the tissue it generates.

What each procedure actually builds

The process inside a microfracture-treated defect begins the moment the surgeon makes each perforation. Blood and fat droplets emerge from the bone marrow, forming a clot across the defect floor. Within that clot, mesenchymal progenitor cells — marrow-derived cells capable of differentiating into several tissue types — begin producing repair tissue. The result is fibrocartilage: structurally useful in the short term, but built primarily from Type I collagen rather than the Type II collagen and glycosaminoglycans that give native articular cartilage its load-bearing resilience. No scaffold is placed; the bone perforation is the intervention itself.

A ChondroFiller injection approaches the problem from a different direction. The cell-free Type I/III collagen hydrogel is delivered under ultrasound guidance as an outpatient procedure — the subchondral bone plate is left untouched. Once in position, the gel sets within the defect and provides a three-dimensional structural template into which the patient's own progenitor cells migrate from the surrounding tissue, progressively depositing matrix over subsequent weeks. A 2025 ex vivo study lends direct biological support to this sequence: DNA content in ChondroFiller-treated defects increased 2.4-fold by day 14, with progressive collagen and glycosaminoglycan deposition thereafter, consistent with the cartilage maturation signal observed on MOCART MRI in clinical follow-ups.

Keeping the subchondral bone plate intact carries a practical consequence beyond the immediate repair: the mechanical foundation beneath the new tissue is preserved, and the subchondral architecture remains available should any further treatment be required in the future.

Why the gap stays hidden for the first two years

Standard outcome measures — IKDC scores, Lysholm knee ratings, VAS pain scales — capture how patients feel at a given point in time. At 12 to 24 months after treatment, those scores are often statistically comparable between microfracture and ChondroFiller-treated patients. For most people, both joints feel meaningfully better than before. This is not a paradox; it is what early fibrocartilage fill looks like symptomatically before cumulative load takes its toll.

MRI tells a different story at the same timepoints. Where MOCART scoring has been used — a validated cartilage-repair MRI protocol that assesses fill degree, surface integrity, and lateral integration with surrounding tissue — ChondroFiller-treated defects consistently show higher defect fill rates and better integration with adjacent native cartilage. The Schneider 2016 multicenter study documented perfect lateral integration from early follow-up and progressive scaffold maturation on MOCART imaging through to 12 months, even as clinical scores were already good. The structural advantage precedes the clinical one.

Why the lag? Fibrocartilage performs adequately under light and moderate load. It is under sustained, repetitive joint stress that its relative lack of glycosaminoglycans and Type II collagen begins to matter. The tissue micro-fractures, thins, and loses its cushioning properties gradually rather than suddenly — which is why the transition from 'scan looks fine' to 'something has changed' tends to happen over months, not overnight. At a population level, this symptomatic transition falls most commonly in the three-to-five-year window post-microfracture, though the timeline varies with defect size, patient age, and activity level. By the time symptoms worsen, the structural divergence that was visible on MRI at 18 months has become clinically apparent.

What the clinical evidence actually shows

The strongest comparative data comes from Silva et al. (2020, PMC7322236), which randomised patients to either microfracture or autologous collagen-induced chondrogenesis (ACIC) — a scaffold-based approach sharing the same rationale as ChondroFiller injection. Both groups showed significant IKDC and SF-36 improvements from baseline at six and 24 months. By the two-year mark, however, the ACIC group recorded meaningfully better scores on both measures. One distinction is worth noting: ACIC uses a collagen scaffold augmented with bone marrow aspirate, making it closely analogous to ChondroFiller but not identical. The result is a strong directional signal rather than a direct equivalence.

The only dedicated ChondroFiller-versus-microfracture RCT (Schneider, 2016) ran into a fundamental problem: six of the ten patients allocated to microfracture declined surgery, making a controlled comparison impossible. The within-group ChondroFiller data remains informative — IKDC improved significantly by month three and was sustained at 12 months, with MOCART MRI confirming progressive scaffold integration — but it cannot answer the comparative question on its own.

The evidence gap deserves a plain statement. No adequately powered, completed randomised trial has followed patients beyond two years directly comparing ChondroFiller injection against microfracture. For a patient feeling well at 18 months post-microfracture, the published data can describe a plausible structural trajectory — fibrocartilage under cumulative load — but it cannot assign a reliable individual risk figure at five years. The mechanistic and imaging evidence is coherent and convergent across multiple study types; what is missing is the long-term clinical trial to confirm that picture at scale.

Who sees the biggest difference in outcomes

Neither treatment delivers uniform outcomes across all patients, and the size of the divergence described in previous sections depends heavily on who is being treated.

For microfracture, the evidence points to a fairly well-defined ideal candidate: patients aged 45 or younger, with a focal defect smaller than 9 mm in diameter and no background degenerative change. In that group, success rates in published series reach 75–80%. Outside those parameters — in older patients, larger lesions, or joints with low-grade osteoarthritis — outcomes decline sharply, and the fibrocartilage formed under less favourable conditions tends to be less durable from the outset.

ChondroFiller injection is not immune to the same OA-grade dependency. The five-year hip cohort data (n=26) found that 17 of 21 evaluable patients achieved good or excellent results overall — but patients with Tönnis grade 2–3 osteoarthritis had poor outcomes, confirming that advanced degenerative change limits what any scaffold-based approach can achieve.

The practical implication is that the divergence after two to three years is most pronounced in older patients or those with moderate degenerative change: fibrocartilage is least mechanically durable in this group, and the joint environment may also reduce the scaffold's capacity to recruit progenitor cells effectively.

Defect size adds a further moderating layer. Microfracture was historically applied to defects under 2 cm²; ChondroFiller injection is indicated up to 3 cm², extendable to 6 cm². In younger patients with small, clean defects and healthy surrounding bone, the outcome gap between the two approaches at two to three years is narrower and may not become clinically significant within five years. The divergence that matters most — and that these decisions should centre on — occurs when patients fall outside microfracture's ideal profile.

The recovery window that determines whether the scaffold succeeds

The scaffold works — but it needs time to do so. A 2024 in vitro study measured cartilage damage under cyclic loading of 33 N applied directly to a ChondroFiller-treated defect in its immediate post-application state; damage scores were no better than in an untreated control. The finding is a mechanistic caution from bench data, not a clinical outcome result, but its implication is straightforward: the collagen gel must be allowed to stabilise and recruit host cells before it can bear meaningful joint load. That process takes roughly six to twelve weeks.

Loading the joint too early during this window risks displacing or disrupting the scaffold before hyaline-like matrix has had the chance to form — which would partly explain why outcome comparisons between ChondroFiller injection and microfracture sometimes show more variation than the mechanistic evidence predicts. A poorly managed rehabilitation protocol is a confounder, not an inherent property of the treatment.

That reframing matters for how patients choose a provider. The technical placement of the scaffold is one variable; the structured protection period afterwards is another of equal importance. Where both are managed carefully, the early instability becomes a predictable, recoverable part of the recovery arc rather than a risk that persists throughout it. For patients in London assessing whether a ChondroFiller injection is suitable for their defect, the London Cartilage Clinic on Harley Street — the UK certified delivery centre — offers an initial assessment at londoncartilage.com.

1. [1] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Hand-minced cartilage versus microfracture for the repair of articular cartilage defects: A propensity score matched-pair analysis with 2-year follow-up. (2025). https://doi.org/10.1002/ksa.12728 https://doi.org/10.1002/ksa.12728
4. [4] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002